Results 191 to 200 of about 908,413 (222)
Acquired Hemophilia A: A Concise Review [PDF]
American Journal of Hematology, 2005 AbstractAcquired hemophilia A is a rare but severe autoimmune bleeding disorder. It is more frequent in the elderly and results from the presence of autoantibodies directed against clotting factor VIII. In this review, we briefly report on the present state of knowledge regarding acquired hemophilia A, analyzing its epidemiology, pathogenesis ...
Giorgio Gandini +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Immunotherapy of acquired hemophilia A
Hematology, 2023Abstract Acquired hemophilia A (AHA) is an autoimmune disorder characterized by the formation of autoantibodies that neutralize the function of coagulation factor VIII. Immunosuppressive therapy (IST) with glucocorticoids, cyclophosphamide, rituximab, or combinations thereof is the standard of care to suppress autoantibody formation and ...
openaire +2 more sources
Acquired hemophilia in malignancy
Thrombosis Research, 2012Acquired hemophilia is a rare but potentially morbid complication in patients with cancer. It may be seen in patients with hematologic neoplasms (usually lymphoproliferative disorders) or with solid tumors. Although the presence of an underlying malignancy portends a worse outcome, the literature suggests that the usual principles of treatment ...
Brandi N, Reeves, Nigel S, Key
openaire +2 more sources
Acta Medica Scandinavica, 1980
ABSTRACT. Acquired hemophilia A due to antibodies of factor VIII procoagulant activity is rare. This paper reports 11 such patients followed up for long periods. They exemplify various forms of associated disorders. Four of them have died from hemorrhages, 4 have had complete remission and 3 are still alive with persistent inhibitors.
I M, Nilsson, S, Lamme
openaire +2 more sources
ABSTRACT. Acquired hemophilia A due to antibodies of factor VIII procoagulant activity is rare. This paper reports 11 such patients followed up for long periods. They exemplify various forms of associated disorders. Four of them have died from hemorrhages, 4 have had complete remission and 3 are still alive with persistent inhibitors.
I M, Nilsson, S, Lamme
openaire +2 more sources
Emicizumab for the treatment of acquired hemophilia A
Blood, 2021Abstract Acquired hemophilia A (AHA) is a severe bleeding disorder caused by inhibiting autoantibodies to coagulation factor VIII (FVIII). For hemostatic treatment, bypassing agents and human or porcine FVIII are currently standard of care.
Paul Knoebl +5 more
openaire +2 more sources
Acquired Hemophilia A: A Case Report
Journal of Pharmacy Practice, 2019Hemophilia A, also known as factor VIII deficiency, is a rare disorder caused by an insufficient level of factor VIII, an essential clotting protein. Hemophilia A can be inherited or acquired. Inherited hemophilia A is caused by a mutation to the factor VIII gene on the X chromosome, which is commonly passed down from parents to children.
Mark, Shen +5 more
openaire +2 more sources
Surgery-associated acquired hemophilia A
Annals of Hematology, 2001We present two patients who acquired factor VIII antibodies in the immediate postoperative period. One patient was receiving warfarin that was temporarily discontinued but reintroduced after the procedure. Preoperatively, none gave a history of bleeding, even with past surgeries, and both had normal coagulation tests. Within days of surgery, hemorrhage
G, Theodossiades +4 more
openaire +2 more sources
[Rinsho ketsueki] The Japanese journal of clinical hematology, 2020
Acquired hemophilia A (AHA) is a bleeding disorder due to the autoantibody (inhibitor) production targeting blood coagulation factor VIII. It is characterized by a sudden onset, and it often causes extensive and severe bleeding in soft tissue. The incidence of AHA is 1.48 cases per 1 million individuals per year and is common among postpartum women and
openaire +1 more source
Acquired hemophilia A (AHA) is a bleeding disorder due to the autoantibody (inhibitor) production targeting blood coagulation factor VIII. It is characterized by a sudden onset, and it often causes extensive and severe bleeding in soft tissue. The incidence of AHA is 1.48 cases per 1 million individuals per year and is common among postpartum women and
openaire +1 more source
Rituximab in the Treatment of Acquired Hemophilia
Annals of Pharmacotherapy, 2006Objective: To review published literature evaluating the use of rituximab for treatment of acquired hemophilia. Data Sources: An English-language literature search was conducted using MEDLINE (1966–January 2006).
openaire +2 more sources